Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2)

Posted on by friebelwv
  • Autoren: Volker Moebus, Helmut Forstbauer, Grischa Wachsmann, Andreas Schneeweiss, Angelika Ober, Ekkehard von Abel, Petra Krabisch, Heinz-Gert Hoeffkes, Karin Kast, Bernd Christensen, Michael Niedermeier, Mustafa Deryal, Christoph Uleer, Yvonne Fauster, Thomas Goehler, Sibylle Loibl, Valentina Nekljudova, Gunter Von Minckwitz
  • ASCO 2013